Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Sonelokimab Demonstrates Psoriatic Arthritis Improvements Over Placebo

Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.

Bridging the Treatment Gap in Pediatric Psoriasis and PsA With Guselkumab, With Vimal H. Prajapati, MD

Q3 2025 saw a number of exciting approvals and data on promising therapies in development.

Q3 2025 Recap: Rheumatology News and Updates

The rheumatology month in review emphasizes new approvals and the latest comparative research.

7 Rheumatology Headlines You Missed in September 2025

The approval makes guselkumab the first and only IL-23 inhibitor approved for these pediatric indications and was based on data from the phase 3 PROTOSTAR study.

FDA Approves Guselkumab (Tremfya) for Pediatric Plaque Psoriasis, Psoriatic Arthritis

Risankizumab shows significant and lasting improvements in psoriatic arthritis symptoms, addressing multiple disease domains and enhancing patient quality of life.

Risankizumab Shows Durable GRAPPA Improvements for PsA

A new meta-analysis has contrasted the association between the 2 conditions against the general population, psoriasis, rheumatoid arthritis, and ankylosing spondylitis.

Psoriatic Arthritis Strongly Associated with Metabolic Syndrome and Components

Combining golimumab with methotrexate reduced corticosteroid reliance and maintained efficacy in psoriatic arthritis.

Adding Golimumab to Treatment Regimen Reduced Rescue Corticosteroid Use in People With Early PsA

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

Closing the Gap: Collaborating Care to Improve Outcomes in Psoriasis and Psoriatic Arthritis

Recent phase 3 trials reveal promising results for Duravancinib in treating psoriatic arthritis, showcasing efficacy and a strong safety profile.

Validating Deucravacitinib’s Anticipated Expansion to Psoriatic Arthritis, with Philip Mease, MD

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.